Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance

  • Authors:
    • Jiwen Cheng
    • Yanke Chen
    • Pu Zhao
    • Na Li
    • Jianwen Lu
    • Jianhui Li
    • Zhengwen Liu
    • Yi Lv
    • Chen Huang
  • View Affiliations

  • Published online on: March 21, 2017     https://doi.org/10.3892/ol.2017.5882
  • Pages: 3859-3865
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs/miRs) have been identified as important post-transcriptional regulators in healthy liver physiology and liver diseases. However, the clinical significance of miR-638 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to investigate the status of miR‑638 expression in HCC and to determine its clinical significance. The expression of miR‑638 was evaluated in 60 HCC tissues samples and HCC SMMC‑7721, HepG2 and Hep3B cell lines using reverse transcription‑quantitative polymerase chain reaction. The association between the expression of miR-638 and the clinicopathological characteristics of patients with HCC was analyzed. The proportion of HCC patients with low miR‑638 expression was identified as 68.3% (41/60). Furthermore, significantly lower miR‑638 expression was identified in HCC tissue samples compared with the healthy control group (P=0.031). miR‑638 expression was significantly lower in SMMC‑7721 (P=0.021), HepG2 (P=0.005) and Hep3B (P=0.003) cells compared with the healthy human hepatic HL‑7702 cell line. In addition, miR‑638 expression was correlated with α‑fetoprotein levels (P=0.042) and portal vein invasion (P=0.025). The area under curve was identified as 0.71 (95% confidence interval=0.63‑0.79; P=0.001). The cut‑off value for miR‑638 was the median 2-Δ∆Cq=0.125. In conclusion, miR‑638 may be involved in the progression of HCC and act as a potential biomarker for the prediction of HCC.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng J, Chen Y, Zhao P, Li N, Lu J, Li J, Liu Z, Lv Y and Huang C: Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance. Oncol Lett 13: 3859-3865, 2017
APA
Cheng, J., Chen, Y., Zhao, P., Li, N., Lu, J., Li, J. ... Huang, C. (2017). Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance. Oncology Letters, 13, 3859-3865. https://doi.org/10.3892/ol.2017.5882
MLA
Cheng, J., Chen, Y., Zhao, P., Li, N., Lu, J., Li, J., Liu, Z., Lv, Y., Huang, C."Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance". Oncology Letters 13.5 (2017): 3859-3865.
Chicago
Cheng, J., Chen, Y., Zhao, P., Li, N., Lu, J., Li, J., Liu, Z., Lv, Y., Huang, C."Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance". Oncology Letters 13, no. 5 (2017): 3859-3865. https://doi.org/10.3892/ol.2017.5882